Chemo Spain – Leandro Sigman, General Manager
Leandro Sigman, general manager of Chemo, discusses changes in the Spanish market and the company’s strategy to target international markets. The crisis has changed the way companies operate in…
Established over 35 years ago, Chemo operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, both for human and animal health.
While the main offices are located in Madrid, Lugano and Buenos Aires, Chemo is acting worldwide, creating a broad and balanced manufacturing and commercial network across major pharmaceutical markets in Europe, America, Asia and Africa, to address global opportunities and customers` needs.
Chemo`s activity is organized in three synergistic business areas: industrial, branded and biotech, with over 5,000 professionals in more than 40 countries, across four continents, ten state-of-the-art manufacturing facilities, nine specialized R&D centers, 12 commercial offices and 33 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world.
Chemo believes in innovation and sustainable development. The company’s commitment is to improve people`s health and quality of life, providing access to safe, quality and affordable medicines, and to continuously expand its efforts and R&D investment to develop new and better therapies.
Contact details:
Chemo Barcelona
Gran Vía Carlos III, 98 7th floor
08028 Barcelona , Spain.
Tel: + 34 93 330 62 12
Fax: + 34 93 330 27 62
BarcelonaChemo@chemogroup.com
Leandro Sigman, general manager of Chemo, discusses changes in the Spanish market and the company’s strategy to target international markets. The crisis has changed the way companies operate in…
The latest from Spanish pharma, including the wide swathe of COVID-19 syringes, vaccines, masks, and tests being produced in the country, Grifols’ Egyptian entry, a new generation of leadership at…
A roundup of the latest news from Spanish pharma, including J&J’s COVID-19 vaccine trial, the latest developments at Spanish firm PharmaMar which hopes its Aplidin can be used as a…
PharmaMar, a Spanish firm, is beginning Phase II clinical trials for its anti-tumour drug Aplidin to treat coronavirus. The firm’s stocks have soared on the news. PharmaMar is joining…
Building on the topics covered in our March 2019 report, the latest edition of Healthcare & Life Sciences Review Spain takes a closer look at the broader Spanish life sciences…
Juan Carlos Moro Rodríguez, CEO for the Iberia Cluster with DB Schenker, discusses the company’s plans to expand its reach across all forms of transport, offering logistics solutions rather than…
Though still one of the younger and lesser-known outfits inhabiting the European drug development landscape, Irish-headquartered rare disease specialist, Jazz pharma has been making tremendous headway in the onco-haematology and…
In what is a highly competitive and crowded women’s health field in Spain, smaller players are having to be increasingly focused and specialised to carve out a market share. …
Many of the world’s mega-rich are increasingly active philanthropists in the healthcare arena and Spain is no exception with Galician billionaire Amancio Ortega Gaona, the 82-year-old owner of clothing empire…
The global acquisition of GSK’s thrombosis portfolio and subsequent purchase of AstraZeneca’s anaesthesia business have been critical milestones for the maverick South African pharmaceutical outfit Aspen, enabling the company to…
Perhaps the only CEO of a dermo-cosmetics company with a PhD in astrophysics and space technology as well as three years working at NASA under his belt, Isdin’s Juan Naya…
The North-Eastern region of Catalonia is one of Spain’s most prosperous and has been allocating increasingly large amounts of its budget towards healthcare. With strong government backing and a robust…
Rocco De Bernardis, managing director for Johnson & Johnson Medical Devices in Spain offers his insights into the company’s local footprint, assesses the situation for value-based healthcare implementation in Spain…
See our Cookie Privacy Policy Here
